Advertisement

Drugs & Aging

, Volume 32, Issue 10, pp 849–856 | Cite as

Prevalence of Potential and Clinically Relevant Statin–Drug Interactions in Frail and Robust Older Inpatients

  • Michele Thai
  • Sarah Hilmer
  • Sallie-Anne Pearson
  • Emily Reeve
  • Danijela GnjidicEmail author
Original Research Article

Abstract

Background

A significant proportion of older people are prescribed statins and are also exposed to polypharmacy, placing them at increased risk of statin–drug interactions.

Objective

To describe the prevalence rates of potential and clinically relevant statin–drug interactions in older inpatients according to frailty status.

Methods

A cross-sectional study of patients aged ≥65 years who were prescribed a statin and were admitted to a teaching hospital between 30 July and 10 October 2014 in Sydney, Australia, was conducted. Data on socio-demographics, comorbidities and medications were collected using a standardized questionnaire. Potential statin–drug interactions were defined if listed in the Australian Medicines Handbook and three international drug information sources: the British National Formulary, Drug Interaction Facts and Drug-Reax®. Clinically relevant statin–drug interactions were defined as interactions with the highest severity rating in at least two of the three international drug information sources. Frailty was assessed using the Reported Edmonton Frail Scale.

Results

A total of 180 participants were recruited (median age 78 years, interquartile range 14), 35.0 % frail and 65.0 % robust. Potential statin–drug interactions were identified in 10 % of participants, 12.7 % of frail participants and 8.5 % of robust participants. Clinically relevant statin–drug interactions were identified in 7.8 % of participants, 9.5 % of frail participants and 6.8 % of robust participants. Depending on the drug information source used, the prevalence rates of potential and clinically relevant statin–drug interactions ranged between 14.4 and 35.6 % and between 14.4 and 20.6 %, respectively.

Conclusion

In our study of frail and robust older inpatients taking statins, the overall prevalence of potential statin–drug interactions was low and varied significantly according to the drug information source used.

Keywords

Statin Drug Interaction Simvastatin Rosuvastatin British National Formulary 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Notes

Acknowledgments

The authors would like to acknowledge Jillian Patterson (Data Analyst, Kolling Institute of Medical Research, Northern Clinical School, Sydney, NSW, Australia) for her assistance in the statistical analysis, and Katie Qi (Pharmacy Honours Student, Faculty of Pharmacy, The University of Sydney, Sydney, NSW, Australia) for her assistance with data collection. Danijela Gnjidic is supported by the Australian National Health and Medical Research Early Career Fellowship. Sallie-Anne Pearson is a Cancer Institute NSW Career Development Fellow.

Compliance with Ethical Standards

Funding and Conflicts of Interest

The authors received no funding to write this paper and have no conflicts of interest to declare.

References

  1. 1.
    Morgan TK, Williamson M, Pirotta M, et al. A national census of medicines use: a 24-hour snapshot of Australians aged 50 years and older. Med J Aust. 2012;196(1):50–3.CrossRefPubMedGoogle Scholar
  2. 2.
    Doan J, Zakrzewski-Jakubiak H, Roy J, Turgeon J, Tannenbaum C. Prevalence and risk of potential cytochrome P450-mediated drug–drug interactions in older hospitalized patients with polypharmacy. Ann Pharmacother. 2013;47(3):324–32.CrossRefPubMedGoogle Scholar
  3. 3.
    Johnell K, Klarin I. The relationship between number of drugs and potential drug–drug interactions in the elderly: a study of over 600,000 elderly patients from the Swedish Prescribed Drug Register. Drug Saf. 2007;30(10):911–8.CrossRefPubMedGoogle Scholar
  4. 4.
    Hines LE, Murphy JE. Potentially harmful drug–drug interactions in the elderly: a review. Am J Geriatr Pharmacother. 2011;9(6):364–77.CrossRefPubMedGoogle Scholar
  5. 5.
    Becker ML, Kallewaard M, Caspers PW, et al. Hospitalisations and emergency department visits due to drug–drug interactions: a literature review. Pharmacoepidemiol Drug Saf. 2007;16(6):641–51.CrossRefPubMedGoogle Scholar
  6. 6.
    Gnjidic D, Johnell K. Clinical implications from drug–drug and drug–disease interactions in older people. Clin Exp Pharmacol Physiol. 2013;40(5):320–5.CrossRefPubMedGoogle Scholar
  7. 7.
    Hilmer SN, McLachlan AJ, Le Couteur DG. Clinical pharmacology in the geriatric patient. Fundam Clin Pharmacol. 2007;21(3):217–30.CrossRefPubMedGoogle Scholar
  8. 8.
    Bennett A, Gnjidic D, Gillett M, et al. Prevalence and impact of fall-risk-increasing drugs, polypharmacy, and drug–drug interactions in robust versus frail hospitalised falls patients: a prospective cohort study. Drugs Aging. 2014;31(3):225–32.CrossRefPubMedGoogle Scholar
  9. 9.
    Gnjidic D, Hilmer SN, Blyth FM, et al. High-risk prescribing and incidence of frailty among older community-dwelling men. Clin Pharmacol Ther. 2012;91(3):521–8.CrossRefPubMedGoogle Scholar
  10. 10.
    Wynne HA, Cope LH, Herd B, et al. The association of age and frailty with paracetamol conjugation in man. Age Ageing. 1990;19(6):419–24.CrossRefPubMedGoogle Scholar
  11. 11.
    Johnston C, Hilmer SN, McLachlan AJ, et al. The impact of frailty on pharmacokinetics in older people: using gentamicin population pharmacokinetic modeling to investigate changes in renal drug clearance by glomerular filtration. Eur J Clin Pharmacol. 2014;70(5):549–55.CrossRefPubMedGoogle Scholar
  12. 12.
    Abarca J, Malone DC, Armstrong EP, et al. Concordance of severity ratings provided in four drug interaction compendia. J Am Pharm Assoc. 2004;44(2):136–41.CrossRefGoogle Scholar
  13. 13.
    Olvey EL, Clauschee S, Malone DC. Comparison of critical drug–drug interaction listings: the Department of Veterans Affairs medical system and standard reference compendia. Clin Pharmacol Ther. 2010;87(1):48–51.CrossRefPubMedGoogle Scholar
  14. 14.
    Sweidan M, Reeve JF, Brien JA, et al. Quality of drug interaction alerts in prescribing and dispensing software. Med J Aust. 2009;190(5):251–4.PubMedGoogle Scholar
  15. 15.
    Vitry AI. Comparative assessment of four drug interaction compendia. Br J Clin Pharmacol. 2007;63(6):709–14.PubMedCentralCrossRefPubMedGoogle Scholar
  16. 16.
    Gnjidic D, Le Couteur DG, Blyth FM, et al. Statin use and clinical outcomes in older men: a prospective population-based study. BMJ Open. 2013;3(3):e002333. doi: 10.1136/bmjopen-2012-002333.PubMedCentralCrossRefPubMedGoogle Scholar
  17. 17.
    Afilalo J, Duque G, Steele R, et al. Statins for secondary prevention in elderly patients: a hierarchical Bayesian meta-analysis. J Am Coll Cardiol. 2008;51(1):37–45.CrossRefPubMedGoogle Scholar
  18. 18.
    Roberts CG, Guallar E, Rodriguez A. Efficacy and safety of statin monotherapy in older adults: a meta-analysis. J Gerontol A Biol Sci Med Sci. 2007;62(8):879–87.CrossRefPubMedGoogle Scholar
  19. 19.
    Paoletti R, Corsini A, Bellosta S. Pharmacological interactions of statins. Atheroscler Suppl. 2002;3:35–40.CrossRefPubMedGoogle Scholar
  20. 20.
    Bellosta S, Corsini A. Statin drug interactions and related adverse reactions. Expert Opin Drug Saf. 2012;11(6):933–46.CrossRefPubMedGoogle Scholar
  21. 21.
    Bottorff MB. Statin safety and drug interactions: clinical implications. Am J Cardiol. 2006;97(8A):27C–31C.CrossRefPubMedGoogle Scholar
  22. 22.
    Neuvonen PJ, Niemi M, Backman JT. Drug interactions with lipid-lowering drugs: mechanisms and clinical relevance. Clin Pharmacol Ther. 2006;80(6):565–81.CrossRefPubMedGoogle Scholar
  23. 23.
    Bellosta S, Paoletti R, Corsini A. Safety of statins: focus on clinical pharmacokinetics and drug interactions. Circulation. 2004;109(23 Suppl 1):Iii50–7.PubMedGoogle Scholar
  24. 24.
    Patel AM, Shariff S, Bailey DG, et al. Statin toxicity from macrolide antibiotic coprescription: a population-based cohort study. Ann Intern Med. 2013;158(12):869–76.CrossRefPubMedGoogle Scholar
  25. 25.
    Bakhai A, Rigney U, Hollis S, Emmas C. Co-administration of statins with cytochrome P450 3A4 inhibitors in a UK primary care population. Pharmacoepidemiol Drug Saf. 2012;21(5):485–93.CrossRefPubMedGoogle Scholar
  26. 26.
    Karimi S, Hough A, Beckey C, Parra D. Results of a safety initiative for patients on concomitant amiodarone and simvastatin therapy in a Veterans Affairs medical center. J Manag Care Pharm. 2010;16(7):472–81.PubMedGoogle Scholar
  27. 27.
    Ming EE, Davidson MH, Gandhi SK, et al. Concomitant use of statins and CYP3A4 inhibitors in administrative claims and electronic medical records databases. J Clin Lipidol. 2008;2(6):453–63.CrossRefPubMedGoogle Scholar
  28. 28.
    Petropoulos JB, Bello-Quintero CE. Frequency of simvastatin prescriptions with potentially interacting medications in a Veterans Affairs health care system. J Manag Care Pharm. 2004;10(3):239–43.PubMedGoogle Scholar
  29. 29.
    Piacentini N, Trifiro G, Tari M, Moretti S, Arcoraci V. Statin-macrolide interaction risk: a population-based study throughout a general practice database. Eur J Clin Pharmacol. 2005;61(8):615–20.CrossRefPubMedGoogle Scholar
  30. 30.
    Egger SS, Bravo AER, Hess L, Schlienger RG, Krahenbuhl S. Age-related differences in the prevalence of potential drug–drug interactions in ambulatory dyslipidaemic patients treated with statins. Drugs Aging. 2007;24(5):429–40.CrossRefPubMedGoogle Scholar
  31. 31.
    Elliott RA. Problems with medication use in the elderly: an Australian perspective. J Pharm Pract Res. 2006;36(1):58–66.CrossRefGoogle Scholar
  32. 32.
    Australian medicines handbook. Adelaide: Australian Medicines Handbook Pty Ltd, 2014.Google Scholar
  33. 33.
    Joint Formulary Committee. British national formulary. 68th ed. London: British Medical Association and Royal Pharmaceutical Society of Great Britain; 2014.Google Scholar
  34. 34.
    Tatro D, editor. Drug interaction facts. Facts and comparisons [database online]. St Louis: Wolters Kluwer Health; 2012.Google Scholar
  35. 35.
    Klasko R, editor. Drug-Reax® system [database on CD-ROM]. Greenwood Village: Thomson Micromedex; 2003.Google Scholar
  36. 36.
    Roughead EE, Kalisch LM, Barratt JD, Gilbert AL. Prevalence of potentially hazardous drug interactions amongst Australian veterans. Br J Clin Pharmacol. 2010;70(2):252–7.PubMedCentralCrossRefPubMedGoogle Scholar
  37. 37.
    Dolton MJ, Pont L, Stevens G, McLachlan AJ. Prevalence of potentially harmful drug interactions in older people in Australian aged-care facilities. J Pharm Pract Res. 2012;42(1):33–6.CrossRefGoogle Scholar
  38. 38.
    Hilmer SN, Perera V, Mitchell S, et al. The assessment of frailty in older people in acute care. Australas J Ageing. 2009;28(4):182–8.CrossRefPubMedGoogle Scholar
  39. 39.
    Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40(5):373–83.CrossRefPubMedGoogle Scholar
  40. 40.
    Folstein MF, Folstein SE, McHugh PR. “Mini-mental state”. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975;12(3):189–98.CrossRefPubMedGoogle Scholar
  41. 41.
    Einarson TR, Metge CJ, Iskedjian M, Mukherjee J. An examination of the effect of cytochrome P450 drug interactions of hydroxymethylglutaryl-coenzyme a reductase inhibitors on health care utilization: a Canadian population-based study. Clin Ther. 2002;24:2126–36.CrossRefPubMedGoogle Scholar
  42. 42.
    Australian Bureau of Statistics. Population by age and sex. Australian states and territories, June 2013. ABS cat. no. 3235.0. 2013. http://www.abs.gov.au/Ausstats/abs@.nsf/mf/3235.0. Accessed 27 Oct 2014.
  43. 43.
    Kerr KP, Mate KE, Magin PJ, et al. The prevalence of co-prescription of clinically relevant CYP enzyme inhibitor and substrate drugs in community-dwelling elderly Australians. J Clin Pharm Ther. 2014;39(4):383–9.CrossRefPubMedGoogle Scholar
  44. 44.
    Westaway KP, Frank OR, Husband AJ, et al. Safe use of statins in elderly people. J Pharm Pract Res. 2014;44(3):138–42.CrossRefGoogle Scholar
  45. 45.
    Ronaldson KJ, O’Shea JM, Boyd IW. Risk factors for rhabdomyolysis with simvastatin and atorvastatin. Drug Saf. 2006;29(11):1061–7.CrossRefPubMedGoogle Scholar
  46. 46.
    Zakrzewski-Jakubiak H, Doan J, Lamoureux P, Singh D, Turgeon J, Tannenbaum C. Detection and prevention of drug–drug interactions in the hospitalized elderly: utility of new cytochrome p450-based software. Am J Geriatr Pharmacother. 2011;9(6):461–70.CrossRefPubMedGoogle Scholar
  47. 47.
    Best O, Gnjidic D, Hilmer SN, Naganathan V, McLachlan AJ. Investigating polypharmacy and drug burden index in hospitalised older people. Intern Med J. 2013;43(8):912–8.CrossRefPubMedGoogle Scholar

Copyright information

© Springer International Publishing Switzerland 2015

Authors and Affiliations

  • Michele Thai
    • 1
  • Sarah Hilmer
    • 2
    • 3
  • Sallie-Anne Pearson
    • 1
  • Emily Reeve
    • 2
    • 3
  • Danijela Gnjidic
    • 1
    Email author
  1. 1.Faculty of PharmacyThe University of SydneySydneyAustralia
  2. 2.Sydney Medical SchoolThe University of SydneySydneyAustralia
  3. 3.Cognitive Decline Partnership Centre, Kolling Institute of Medical ResearchRoyal North Shore HospitalSydneyAustralia

Personalised recommendations